MARKET

ACRS

ACRS

Aclaris Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.08
+0.16
+1.34%
After Hours: 12.08 0 0.00% 16:00 05/25 EDT
OPEN
11.83
PREV CLOSE
11.92
HIGH
12.23
LOW
11.83
VOLUME
196.84K
TURNOVER
0
52 WEEK HIGH
24.00
52 WEEK LOW
9.26
MARKET CAP
804.31M
P/E (TTM)
-8.8830
1D
5D
1M
3M
1Y
5Y
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
Zacks · 05/17 15:53
Recap: Aclaris Therapeutics Q1 Earnings
  Aclaris Therapeutics (NASDAQ:ACRS) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/10 13:08
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of 20.51% and 13.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 12:15
Aclaris Therapeutics Q1 EPS $(0.31) Up From $(0.57) YoY, Sales $1.45M Down From $1.78M YoY
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.31) per share. This is a 45.61 percent increase over losses of $(0.57) per share from the same period last year. The company reported $1.45 million in
Benzinga · 05/10 11:39
BRIEF-Aclaris Therapeutics Reports First Quarter 2022 Financial Results And Provides A Corporate Update
reuters.com · 05/10 11:34
Aclaris Therapeutics GAAP EPS of -$0.31 beats by $0.09, revenue of $1.45M misses by $0.22M
Aclaris Therapeutics press release (NASDAQ:ACRS): Q1 GAAP EPS of -$0.31 beats by $0.09. Revenue of $1.45M (-18.5% Y/Y) misses by $0.22M.
Seekingalpha · 05/10 11:20
-- Earnings Flash (ACRS) ACLARIS THERAPEUTICS Posts Q1 Revenue $1.5M
MT Newswires · 05/10 07:16
Notable earnings before Tuesday's open
ACRS, AFCG, AGEN, AHCO, ALGM, AMRS, ANIP, ARMK, AROC, ARVL, ATNX, AUPH, AVYA, AZEK, OTCPK:BAYZF, BCO, BHC, BLDE, BLDR, BSY, CCO, CEVA, CHH, CMPS, CRNC, CRON, DBD, DCTH, DM, DS,
Seekingalpha · 05/09 15:06
More
No Data
Learn about the latest financial forecast of ACRS. Analyze the recent business situations of Aclaris Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ACRS stock price target is 34.80 with a high estimate of 50.00 and a low estimate of 26.00.
High50.00
Average34.80
Low26.00
Current 12.08
EPS
Actual
Estimate
-0.32-0.24-0.16-0.08
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 154
Institutional Holdings: 67.77M
% Owned: 101.78%
Shares Outstanding: 66.58M
TypeInstitutionsShares
Increased
36
6.99M
New
10
2.84M
Decreased
42
4.08M
Sold Out
30
2.14M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Non-Executive Chairman/Independent Director
Christopher Molineaux
President/Chief Executive Officer/Co-Founder/Director
Neal Walker
Co-Founder/Chief Financial Officer/Secretary
Frank Ruffo
Chief Scientific Officer
Joseph Monahan
Other
James Loerop
Independent Director
Maxine Gowen
Independent Director
William Humphries
Independent Director
Anand Mehra
Independent Director
Vincent Milano
Independent Director
Andrew Powell
Independent Director
Bryan Reasons
Independent Director
Andrew Schiff
No Data
No Data
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drug candidates for immuno-inflammatory diseases. Its drug candidates include ATI-450, ATI-1777, ATI-2138 and Undisclosed- Gut Restricted Program. Its ATI-450 is an investigational oral, small molecule selective mitogen-activated protein kinase-activated protein kinase 2, or MK2, inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777 is an investigational topical soft-JAK inhibitor compound, for the treatment of atopic dermatitis. Its ATI-2138 is an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, as al treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases.

Webull offers kinds of Aclaris Therapeutics Inc stock information, including NASDAQ:ACRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACRS stock methods without spending real money on the virtual paper trading platform.